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ABSTRACT
In genetic medicine, a patient’s diagnosis can mean
their family members are also at risk, raising a question
about how consent and conﬁdentiality should function in
clinical genetics. This question is particularly pressing
when it is unclear whether a patient has shared
information. Conventionally, healthcare professionals
view conﬁdentiality at an individual level and ‘disclosure
without consent’ as the exception, not the rule. The
relational joint account model, by contrast,
conceptualises genetic information as conﬁdential at the
familial level and encourages professionals to take
disclosure as the default position. In this study, we
interviewed 33 patients about consent and
conﬁdentiality and analysed data thematically. Our ﬁrst
theme showed that although participants thought of
certain aspects of genetic conditions—for example, the
way they affect day-to-day health—as somewhat
personal, they perceived genetic information—for
example, the mutation in isolation—as familial. Most
thought these elements were separable and thought
family members had a right to know the latter,
identifying a broad range of harms that would justify
disclosure. Our second theme illustrated that participants
nonetheless had some concerns about what, if any,
implications there would be of professionals treating
such information as familial and they emphasised the
importance of being informed about the way their
information would be shared. Based on these results,
we recommend that professionals take disclosure as the
default position, but make clear that they will treat
genetic information as familial during initial
consultations and address any concerns therein.
INTRODUCTION
Healthcare professionals (HCPs) have a duty to
safeguard individual patients’ rights and interests:
keeping their medical information conﬁdential pro-
tects privacy and engenders trust, while asking
consent to share that information protects their
autonomy. Individual rights and interests, however,
are often intertwined with those of others, which is
especially so in genetic medicine, where one
patient’s diagnosis can indicate that relatives are
also at risk.1 This raises a question about how
consent and conﬁdentiality should function in
genetic medicine. For example, should HCPs share
information with patients’ at-risk relatives if they
seem unlikely to do so themselves? In such
situations, HCPs need to balance their patient’s
privacy and (ostensibly) autonomous decision not
to share with the potential to prevent harm to the
relative. One study suggests explicit refusal to share
is rare in the UK,2 but cases discussed at the UK
Genethics Forum3 suggest that HCPs regularly
encounter and are uncertain how to manage cases
where they are unsure that the patient has shared.
UK guidelines4 state HCPs can disclose personal
information if a patient has explicitly refused
consent when ‘the beneﬁts to an individual or to
society of the disclosure outweigh the public and
the patient’s interest in keeping the information
conﬁdential’. Other UK guidelines5 state that HCPs
should consider the severity and predictability of
the condition, while US guidelines6 suggest that the
risk should be serious, imminent, foreseeable and
likely. The default position, if relying on such
guidelines and on existing norms, is for HCPs to
treat patient information as conﬁdential to them
and disclosure without consent as the exception,
not the rule.
Arguably, this approach to conﬁdentiality and
autonomy is based on an inaccurate conceptualisa-
tion of patients as separate from others, free from
social or familial constraints. By contrast, relational
approaches to autonomy stress that patients
develop their autonomy through social embedded-
ness and engagement with others; that one person’s
choices affect other people’s autonomy; and that
despite wanting to protect their personal interests,
people are interested in maintaining family and
community relationships. Relational approaches are
rooted in communitarian and feminist ethics and
underscore relatives’ moral responsibilities to each
other.7
Along these same lines is the joint account model
of conﬁdentiality, where genetic information is con-
ceptualised as familial and ‘belonging’ to all the
relatives it might affect, not just the individual in
whom it was ﬁrst identiﬁed. One reason the infor-
mation is seen and treated as familial is that HCPs
likely initiated that patient’s test because of familial
information provided without relatives’ explicit
consent. The default position here is for HCPs to
share information that is relevant to at-risk relatives
unless they identify circumstances that would
justify excluding other ‘account holders’ from their
information.8 The joint account model informs
current guidelines from the British Society for
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Genetic Medicine (BSGM) about consent and conﬁdentiality.
The guidelines recommend HCPs use a consent form for
genetic testing that includes a statement such as, “I acknowledge
that my results will sometimes be used to inform the appropri-
ate healthcare of family members” instead of asking patients to
agree or disagree to sharing.9 Others too have suggested HCPs
make clear at the outset they will treat information as
familial.10 11
Foster et al12 have recently suggested that a relational
approach together with the joint account model (relational joint
account herein) would be a workable model in the courts.
Notwithstanding, some have pointed out unresolved issues,
including the fuzzy boundaries of the ‘genetic family,’ and their
competing rights to know and not know13 14 It is unclear what
patients think, because existing empirical studies about consent
and conﬁdentiality are few and limited: they have explored the
issues only brieﬂy; used surveys that lack the nuances of qualita-
tive research; focused narrowly on situations where patients
explicitly refuse to share; and have questionable transferability
to the UK and National Health Service (NHS).15–19 Patients’
views are timely and important to consider, because genetics is
rapidly moving in to the genomic era, meaning the likelihood of
needing to involve family members to clarify a patient’s uncer-
tain result or because of an incidental/additional ﬁnding with
relevance to relatives will increase.20 Our overall aim therefore
was to explore patients’ views, in particular about the relational
joint account, and identify implications to policy and practice.
METHOD
We sent information about our research with a reply slip to colla-
borators in three large genetics centres in the UK, who posted the
information onwards to all recent patients seen for hereditary
cancers and cardiac conditions in the previous 2 years. Online
supplementary ﬁgure S1 shows how the project was framed on
information sheets: we took care to keep the information general
so as not to ‘lead’ participants into one view or another or bias
recruitment towards people who supported information sharing.
Interested parties could return a reply slip to SD in a stamped
addressed envelope. We also posted information on online
condition-speciﬁc support groups. SD contacted those who sent
back a slip or responded online to arrange a suitable time, date,
and, for face-to-face interviews, location. We asked participants
to choose somewhere they could speak with us undisturbed to
keep discussions as conﬁdential as possible.
Discussions about the research topic when we were arranging
the interview were kept general: we refrained from detailing any
arguments about our topic so that participants would later share
their views and experiences with minimal inﬂuence from the
researchers.
This was important because, as an ‘instrument’ of the research,
the qualitative researcher can introduce bias in data collection
and analysis, thus affecting the trustworthiness of the ﬁndings.
We took several steps to minimise this possibility.21 First, our
interview schedule comprised of general, open-ended, and non-
leading questions designed around our research questions and
empirical and conceptual literature. Second, we piloted the
schedule in the ﬁrst interview, after which we discarded unneces-
sary, complex and potentially directive questions. SD conducted
all the interviews to retain consistency in the questions asked
across participants. Thirdly, AL and AF analysed sections of data
independently to enhance reliability and rigour, and these ana-
lyses were discussed and compared. Another way we limited bias
was to frame the purpose of the project and summarise its aims
in a non-leading way in the preamble to each interview (see
online supplementary ﬁgure S1). Since data collection and ana-
lysis were iterative, we were able to identify new and important
questions and areas of ambiguity or tentativeness in the analysis
that could be explored in subsequent interviews. We used general
scenarios about non-disclosures to prompt discussion.
In total, we conducted semistructured interviews with 33
adult participants from England. Interviews lasted around 1 h
and were face-to-face (n=25), by phone (n=5) or Skype (n=3).
Data were analysed thematically.22 Although one participant had
been tested for Huntington’s disease, we focused in interviews
on views about conditions conventionally thought of as amen-
able to medical intervention.
RESULTS
Table 1 contains details about participants. We identiﬁed two
major themes: the ﬁrst about the nature of genetic information
and the second about controlling its ﬂow. Online supplementary
table S2 contains additional supportive quotationsi.
Genetic information should be disclosed
Genetic information is not personal
Almost all participants saw genetic information as essentially
familial, with several saying something akin to “this isn’t my infor-
mation, I don’t own the gene” (P16, hereditary breast/ovarian
cancer (HBOC),F). Participants perceived relatives as having a
right to know about their potential risk and themselves as having
a ‘duty’ (P12,possible HBOC,F) to help them by sharing;
P13:[The information is] only private maybe to the family, but
not particularly private to me. I think it’s probably my family’s
right to know about it, so they should be informed about it, and
it’s not my decision to keep that from them. Outside of the
family then probably yes[it is private], but within the family or
the wider family, then no. (Cardiomyopathy,M)
The view that genetic information is private at a familial
rather than individual level and the perceived duty to consider
the interests of the family aligns with the relational joint
account. Participants said their views would be unchanged even
if they were estranged from their at-risk relatives. Several said a
patient’s refusal to share information would be selﬁsh, with
another saying it would be irresponsible and another ‘a
betrayal’. They also felt genetic information should be used to
progress research and help humanity, not just family.
A tricky situation, but conﬁdentiality is ‘by-the-by’
Some participants talked about how although genetic informa-
tion was familial, it was simultaneously ‘personal’. For example,
P7 (Alport,F) distinguished between her condition and the gene
that caused it: Alport syndrome’s effect on her was personal,
but the genetic information in isolation was not—nor was it
owned by her. This perception hints that the two types of infor-
mation (personal and familial) were linked, but separable.
However, some participants—particularly those who had
experienced non-disclosures in their family—saw this personal-
familial duality as a problematic tension. For example, P30
(HBOC,F), whose sister had kept her diagnosis a secret was
unsure whether and how HCPs could practically and ethically
share the relevant information;
[i]We use the term ‘participant’ to refer to the 33 participants in the
current study and ‘patient’ to refer generally to patients in the NHS. In
addition, when we talk about relatives, we intend to mean that they
were not the HCPs’ patients.
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P30: I felt as if that blood should have been everybody’s, but I
know it’s her blood and it’s her result, but I felt like that result
should then have gone into a bank for any people that may be
affected by it. But I don’t know whether that would ever be
something that you could, because obviously it’s not my blood,
it’s her blood. I think there needs to be a way—because there’s
too many people out there in my situation—where if they are
doing the test that it becomes public for the family. (HBOC,F)
The separation of personal and familial information was difﬁ-
cult to imagine because her sister was the tested person and had
refused to share information. P30’s uncertainty appeared to
stem from sensing that her sister might have ‘owned’ the genetic
information, or had some other special right over it. The reason
for this intuition was that the result was generated by doing a
test on her sister’s body, with her consent and cooperation, and
was contained within her blood. Brock23 has highlighted how
factors such as these explain why one might think a person’s
result is conﬁdential to them. But like Brock, P30 seemed to
conclude that these reasons should not prevent HCPs from
sharing, given the risks to relatives.
Setting aside the practical difﬁculties of sharing information
(eg, HCPs having no contact details for relatives), participants
found it generally acceptable for HCPs to share information
without the tested person’s explicit consent. Participants
thought that this would indeed constitute a breach of patient
conﬁdence, but that this harm was trivial compared with the
beneﬁt of knowing about risk. Here, participants’ views did not
align conceptually with the joint account model, under which
sharing genetic information with family does not constitute a
breach. Yet their views did align with the model in practical
terms (ie, erring on the side of disclosure rather than conﬁ-
dence). Preventing illness that could lead to an avoidable death
was the main justiﬁcation;
P17: I think that (conﬁdentiality) should be by-the-by when you
could be saving somebody’s life. They could have an illness or a
potential illness that’s going to kill them. (Lynch,M)
P3 (Alport,F) saw another beneﬁt: by sharing information
between relatives who were not in contact, HCPs could bring
affected relatives together, who could then support each other
in managing the condition. Some suggested deidentifying infor-
mation before sharing, even though, as they recognised, the
patient’s identity could remain obvious.
P29:[At-risk relatives] should still be able to be told that it’s in the
family and just not who and where it’s come from. [HBOC,F]
Notably, a small minority of participants laid more emphasis
on the importance of HCPs encouraging patients to share infor-
mation themselves. Their main reasons were that receiving
unexpected information from HCPs could distress relatives
(P12, possible HBOC,F; P26,HBOC,F) and disclosure could
erode trust and make people reluctant to reveal information
(P26). P7 (Alport,F) to an extent agreed but felt more con-
ﬂicted: she thought sharing was important to protect lives, but
breaching could violate the patient’s ‘free will’. She described
how even though her Alport syndrome had a personal effect on
her life, the genetic information itself (ie, deidentiﬁed) was not
personal or owned by her. Along with a few others, she high-
lighted the importance of HCPs supporting, encouraging and
exploring what they perceived to be the likely reasons for non-
disclosures: relationship or emotional problems. Crucially, none
thought that HCPs should respect patients’ refusals on the basis
that the information was private and personal to them.
Broad harms justify disclosure
A frequently cited reason for disclosure (even without consent)
was that it would enable relatives to make timely choices: they
thought relatives should be tested and offered treatment/inter-
vention as soon as their risk was apparent. For this reason, most
participants also thought HCPs should spend only limited time
encouraging reluctant patients to tell relatives themselves. They
saw risk as ‘a ticking time bomb’ (P9,FAP,F) and held this view
regardless of the timing of onset. Relatedly, participants thought
HCPs should share information to allow relatives to make
reproductive decisions. To an extent, this view depended on the
condition: P26 (HBOC,F) said conditions more ‘debilitating’
than hereditary cancer would warrant disclosure based on
reproductive risk, but P24 (HBOC,F) and P9 (FAP,F) said cancer
warranted it too. Either way, harm did not have to be imminent
to justify disclosure without consent.
Table 1 Participant details
Sex 22 female (F); 11 male (M)
Condition Hereditary breast/ovarian cancer (HBOC) (n=14: n=5 had cancer before test)
Lynch syndrome (n=8: n=6 had cancer before test)
Familial adenomatous polyposis (FAP) (n=3: n=1 had cancer before test)
Alport syndrome (n=4)
Hereditary cardiomyopathy (n=2)
Hereditary haemochromatosis (n=1)
Huntington’s disease (n=1)
Test result All tested and diagnosed as positive except
n=2 tested negative (P9,cardiomyopathy,F; P11,Huntington,F)
n=2 untested (P5,Lynch,F; P12,HBOC,F)
Learning about
risk
Most learnt of their risk at the same time as siblings and other close relatives. Seven were the first to be tested and told family about their risk
immediately, often before having the test/getting their result
Disclosure None had withheld information although a few had not told distant relatives yet, mostly because they had no contact details. Three participants’
relatives did not share information about risk with them.
P5 (possible Lynch,F): cousin was withholding his exact mutation so she could not have a definitive test.
P18 (HBOC,F): sister did not want to tell her about risk directly so asked her General Practitioner (GP) to do so. P18 found out months later as GP
failed to pass the message on.
P30 (HBOC,F): sister did not share her HBOC diagnosis. P30 found out because a nurse mentioned it during an appointment with the affected
withholding sister, which another sister attended. The latter shared the information
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Participants moreover identiﬁed non-medical harms and
beneﬁts that they thought it important HCPs consider, such as
the damage that delayed diagnosis could have on family rela-
tionships and psychological well-being. For these reasons, par-
ticipants thought there could be good arguments to disclose
conditions not amenable to medical intervention, such as early
onset Alzheimer disease, although they perceived such situa-
tions to be more complicated because of the distress disclosure
could cause. Overall, participants’ views thus aligned with the
criticism of the conventional approach to breaching conﬁdenti-
ality, that it entails a too narrow deﬁnition of justiﬁable
harm.8
Having some control over information is desirable
Choice has upsides and downsides
Despite discussing genetic information as familial, participants’
attitudes towards their information were not completely permis-
sive. Some worried that if HCPs saw and treated genetic infor-
mation as familial, they would share it without the patient’s
knowledge, permission or consent. These participants under-
standably expressed a preference that HCPs tell them how their
information would be used (although they generally trusted
HCPs to share information appropriately).
Looking more closely at types of permission and consent, par-
ticipants struggled with whether HCPs should ask patients
whether they agreed or disagreed to them sharing information
with relatives or whether HCPs should share patients’ informa-
tion as a condition of them receiving care. Some defended using
the latter, saying that asking patients’ permission would undesir-
ably give them an opportunity to refuse. Nevertheless, this solu-
tion was pragmatic rather than optimal and there were some
perceived disadvantages;
P24: In some ways it would make you feel a bit powerless, that
this isn’t your information to control and I feel like that wouldn’t
be as good. I would personally feel like ‘well this is my test, this
is my information, and I should be able to tell people when and
how I please’. (HBOC,F)
The perceived lack of choice made such participants defen-
sively sway towards a view that ‘genetic information is personal’.
Nonetheless, P24 continued;
P24: But I feel like at the same time it is important for other
people to know and if you do get someone who (says), ‘no, it
doesn’t affect them’ or ‘I don’t feel comfortable talking about it’,
then in that case other people really do need to know, so then it
would be good catch-all for them. It’s very, it’s difﬁcult.
Even participants who had been ‘victims’ of non-disclosure
found permissions problematic. P5 (possible Lynch,F) had said
initially that HCPs should have overridden her cousin’s refusal
to share his exact Lynch syndrome mutation. Yet later, she said;
P5: It’s your information to do with what you want. I suppose
you should always have the choice[about sharing], but I wouldn’t
understand why you wouldn’t share it.
I: But do you feel it’s your information?
P5: It is, isn’t it? I suppose initially it is. But then, it’s not is it?
Because you’re part of a family who could be affected with it, so
it’s not your information, they should be told. It’s a very difﬁcult
one. Yeah, I suppose initially it is your information.
I: What makes it yours?
P5: I suppose they’ve taken your blood from you, so it’s yours.
That’s how I would think of it.
Like others (eg, P30), this participant sensed the tested
person should have some special rights over the information
because it came from their blood, but it was difﬁcult to articu-
late the reasoning behind this intuition and identify the rights,
considering the relevance of this information to relatives.
Notably, other participants who thought patients should be
given an ‘agree/disagree’ option additionally went on to say any
‘disagrees’ should be overruled by HCPs, in that information
should be shared anyway, making the purported choice seem
like a token gesture. They thought it important that HCPs ask
permission to share, but also that patients not see this as an
opportunity to refuse. Participants seemed to think that by
asking permission, HCPs were respecting the information’s per-
sonal nature and by agreeing to share it, patients were respecting
its familial nature.
Something that appeared to exacerbate many participants’
struggle with permission was a reluctance to speak for everyone.
They did not feel stigmatised by their diagnosis themselves so
did not think stigma was a good reason for a patient’s non-
disclosure, yet they realised other people might feel differently.
Relatedly, P10 (HBOC,F) worried that if HCPs could share
genetic information without consent, they could share other
(more stigmatising) medical information without consent as
well. One thing participants agreed upon was that they did not
want or expect HCPs to ask permission each time before they
shared information with a newly identiﬁed at-risk relative. They
thought this process would delay relatives receiving care and did
not want to be responsible for such delays.
Confusion about the law
Participants were unsure how HCPs could share information
legally, for example, in line with the Data Protection Act (P23,
Lynch,M). This ﬁnding raises the point that a person who with-
holds information might do so on the assumption that laws
would prevent HCPs from sharing. One participant, who was
an allied HCP in the NHS, said HCPs too worried about legal-
ity. She felt, however, that a shift towards HCPs getting permis-
sion to share early in consultations and then using information
appropriately to help others was much needed;
P2: Even if it’s open house, I think there will always be an indi-
vidual one-to-one and that is where you need to get the consent.
It’s incredibly difﬁcult for geneticists; they’ve been brought up
with consent, consent, consent, you must keep everything quiet.
[They] know something about people that is so important,[but]
their own ways are going to cause them to be reluctant. You can
understand that. (Alport,F)
DISCUSSION
We have shed light on the views of people tested for, or at risk
of, hereditary conditions regarding consent, conﬁdentiality and
information-sharing in genetic medicine. Much like HCPs do in
practice, participants identiﬁed and balanced the harms and ben-
eﬁts of HCPs sharing information. Generally, participants had
altruistic tendencies and thought of genetic information as
familial, which aligns with the central thesis of the relational
joint account model. Overall, participants supported sharing,
but noted two reasons HCPs might ﬁnd it difﬁcult to share if a
patient had refused consent. First, the result had been generated
from one person’s blood, which might confer special rights for
them over it and second, personal information (the condition
and its effect on the individual) and familial information (the
familial mutation) were entangled. Nevertheless, they could not
articulate what special rights a tested person might have over
the result that would justify non-disclosure and thought HCPs
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should override any refusals, disentangling and sharing informa-
tion where possible. Participants also thought broad harms justi-
ﬁed sharing, that is, not just imminent and likely, or just
physical, risks. Indeed, as others have argued, criteria such as
imminence and seriousness are difﬁcult to deﬁne and too
restrictive because genetic medicine deals with risk rather than
certainty.24 In this way participants’ views were different to
General Medical Council4 and British Medical Association5
guidelines and aligned more with those from the BSGM.
Our ﬁnding in support of sharing contrasts two studies in
which the majority of participants disagreed that HCPs should
be able to disclose patients’ test results to immediate relatives
without written consent.15 16 The reason for the difference is
likely to be that both of these were quantitative studies, where
participants’ views were ascertained using a single question on
a survey. Our results supported three other studies where
researchers sought relatively more nuanced views, albeit brieﬂy
and without reference to the relational joint account. In those
studies, participants thought HCPs had an obligation to share
information to protect relatives from harm and save lives.17–19
The right not to know was not raised in our study, even
though HCPs in another study used this as a reason not to
share.25
Based on participants’ support for sharing, we recommend a
shift in current practice. That is, for HCPs at the outset, before
even seeking consent, to take as their default position that they
will share information (where it is clinically relevant to do so)
rather than keep it conﬁdential to one person. If the patient
later refuses to disclose some information, HCPs should of
course weigh this in the balance when considering whether to
move away from the default position. Even then, however, we
consider that HCPs might be able to disclose by separating
information relevant to the family from that which is relevant
only to the individual. We additionally recommend that HCPs
discuss with patients at the outset that they will treat elements
of the information as familial and address any apprehensions
patients may have then. Such discussion would be valuable: a
major concern for participants was that professionals might
share information unawares to them. For this reason, many par-
ticipants wanted an agree/disagree choice about sharing. We are
not recommending that HCPs give patients an explicit choice,
but argue that upfront discussion would enable and empower
patients to participate actively in conversations about their infor-
mation. In such discussions, HCPs might highlight ways that
sharing over non-disclosure can be beneﬁcial for individual
patients: our study and others suggest that family secrets might
damage relationships, whereas informed relatives could support
each other.26
Limitations and further research
A possible limitation of our work is that we did not include an
exhaustive review of ethical arguments surrounding consent,
conﬁdentiality and information-sharing. We also based our
conclusions on the analysis of the views of a small set of par-
ticipants, which we, as researchers, distilled and mediated.
Nevertheless, as many empirical ethics researchers have
argued,27 there are important insights to be gained from even
small empirical research studies, and participants’ views can be
weighed in the balance and contribute to the quality of ongoing
ethical arguments.
More research could be useful, however, since our analyses
and conclusions might have differed were other participants
interviewed. Despite us asking clinicians and genetic counsellors
to send information speciﬁcally to anyone who had withheld
information or had their information shared without consent, no
such person participated, meaning participants’ considerations
about non-disclosures were mostly hypothetical. We also did not
collect details such as socioeconomic status and educational level.
Although we would not have been able to make conclusions
about the impact of such factors on views using qualitative meth-
odology, it might be worthwhile to explore these questions in
future quantitative research. This is particularly since people with
higher incomes have been shown as more likely than those with
lower incomes to be concerned about conﬁdentiality and to think
that genetic information deserves special protections in medical
records.16 Religion, age, gender, and marital status have too been
shown to impact on views about sharing genetic test results.28 We
additionally call for further research about the practicalities of
sharing information.
CONCLUSION
Our ﬁndings illuminate views about consent, conﬁdentiality and
information-sharing and show overall support for the relational
joint account. We hope our conclusions help HCPs gain a better
insight into how to approach consent and conﬁdentiality—not
just for patients who explicitly refuse to share, but for all
patients—and encourage them to take appropriate familial
sharing as the starting point. In our wider project, we will be
exploring how HCPs’ views compare with our participants’
views that genetic information should be disclosed and high-
lighting what, if any, consensus exists among them.
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